But an association with improved overall survival failed to reach statistical significance ...

Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted ...

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Metastatic breast cancer (MBC) or stage IV breast cancer is when cancer spreads beyond the breast and regional lymph nodes to distant sites like bones, liver, lungs or brain. Breast cancer cells ...

Chemotherapy reshapes gut bacteria in ways that send powerful signals throughout the body. These signals reprogram immune ...

Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in ...

In patients with metastatic breast cancer (BC), the prevalence of brain metastases increased with each treatment line, rising the most among patients with hormone receptor (HR)–negative, human ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.